MA56205A - Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation - Google Patents

Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation

Info

Publication number
MA56205A
MA56205A MA056205A MA56205A MA56205A MA 56205 A MA56205 A MA 56205A MA 056205 A MA056205 A MA 056205A MA 56205 A MA56205 A MA 56205A MA 56205 A MA56205 A MA 56205A
Authority
MA
Morocco
Prior art keywords
pcrv
antibodies
bind
compositions
methods
Prior art date
Application number
MA056205A
Other languages
English (en)
Inventor
Alida Coppi
Christos Kyratsous
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA56205A publication Critical patent/MA56205A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA056205A 2019-06-11 2020-06-10 Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation MA56205A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962860146P 2019-06-11 2019-06-11

Publications (1)

Publication Number Publication Date
MA56205A true MA56205A (fr) 2022-04-20

Family

ID=71948699

Family Applications (2)

Application Number Title Priority Date Filing Date
MA54975A MA54975B1 (fr) 2019-06-11 2020-06-10 Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
MA056205A MA56205A (fr) 2019-06-11 2020-06-10 Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA54975A MA54975B1 (fr) 2019-06-11 2020-06-10 Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation

Country Status (17)

Country Link
US (2) US11655286B2 (fr)
EP (1) EP3983015A1 (fr)
JP (1) JP2022536469A (fr)
KR (1) KR20220019755A (fr)
CN (1) CN113966343A (fr)
AU (1) AU2020292283A1 (fr)
BR (1) BR112021023335A2 (fr)
CA (1) CA3140075A1 (fr)
CL (4) CL2021003215A1 (fr)
CO (1) CO2021015254A2 (fr)
EA (1) EA202192810A1 (fr)
IL (1) IL288727A (fr)
MA (2) MA54975B1 (fr)
MX (1) MX2021015156A (fr)
PH (1) PH12021552903A1 (fr)
SG (1) SG11202112462RA (fr)
WO (1) WO2020252029A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE050985T2 (hu) * 2011-11-07 2021-01-28 Medimmune Ltd Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák
FR3114970B1 (fr) * 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
CN114404614B (zh) * 2022-01-28 2024-04-23 上海交通大学 一种靶向铜绿假单胞菌的免疫脂质体及其制备方法和应用
CN117222740A (zh) * 2022-06-07 2023-12-12 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
WO2024206669A2 (fr) * 2023-03-29 2024-10-03 Virtuoso Binco, Inc. Anticorps pour cibler cd47 et b7h3 et leurs méthodes d'utilisation
AU2024307442A1 (en) 2023-06-28 2026-02-19 Universität Zu Köln Neutralizing human monoclonal antibodies against p. aeruginosa
CN118530352B (zh) * 2024-05-11 2025-03-25 重庆原伦生物科技有限公司 一种特异性识别铜绿假单胞菌PcrV的抗体及其应用
CN118440191B (zh) * 2024-05-11 2025-06-10 重庆原伦生物科技有限公司 一种抗铜绿假单胞菌PcrV抗体的制备及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
CA2352572C (fr) 1998-12-01 2010-04-20 Abbvie Biotherapeutics Inc. Anticorps anti-interferon gamma humanises
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002064161A2 (fr) 2001-01-26 2002-08-22 Mcw Research Foundation, Inc. Procede et compositions d'immunisation avec l'antigene v de pseudomonas
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
CA2706732A1 (fr) * 2007-11-30 2009-06-11 Kalobios Pharmaceuticals, Inc. Anticorps diriges contre l'antigene pcrv de pseudomonas aeruginosa
WO2009088032A1 (fr) 2008-01-10 2009-07-16 Shionogi & Co., Ltd. Anticorps dirigé contre pcrv
CN101910179B (zh) 2008-01-11 2013-06-19 伊莱利利公司 糖皮质激素受体调节剂及使用方法
CN102341496B (zh) * 2009-03-11 2014-07-02 盐野义制药株式会社 具有抗绿脓杆菌作用的人源化PcrV抗体
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
WO2012122533A2 (fr) 2011-03-10 2012-09-13 The University Of Chicago Compositions et procédés liés à des anticorps contre les protéines staphylococciques isda ou isdb
US10143186B2 (en) 2010-02-08 2018-12-04 Regeneron Pharmaceuticals, Inc. Common light chain mouse
HUE050985T2 (hu) * 2011-11-07 2021-01-28 Medimmune Ltd Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák
EP2793944B1 (fr) 2011-12-23 2025-10-08 Nicholas B. Lydon Immunoglobulines et variants dirigés contre des microbes pathogènes
KR20150082367A (ko) * 2012-11-06 2015-07-15 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
EP3383884A4 (fr) 2015-11-30 2019-07-31 Medimmune Limited Procédé de prévention ou de traitement d'une pneumonie nosocomiale
GB201602156D0 (en) 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
SG11202001160XA (en) 2017-09-29 2020-03-30 Regeneron Pharma Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof

Also Published As

Publication number Publication date
MA54975B1 (fr) 2023-08-31
EA202192810A1 (ru) 2022-03-05
KR20220019755A (ko) 2022-02-17
SG11202112462RA (en) 2021-12-30
US20230322907A1 (en) 2023-10-12
WO2020252029A1 (fr) 2020-12-17
CL2023003695A1 (es) 2024-06-14
EP3983015A1 (fr) 2022-04-20
CL2021003215A1 (es) 2022-09-30
US20200392210A1 (en) 2020-12-17
MA54975A1 (fr) 2022-05-31
US12552856B2 (en) 2026-02-17
BR112021023335A2 (pt) 2022-01-04
AU2020292283A1 (en) 2021-12-23
MX2021015156A (es) 2022-01-18
CA3140075A1 (fr) 2020-12-17
JP2022536469A (ja) 2022-08-17
IL288727A (en) 2022-02-01
US11655286B2 (en) 2023-05-23
PH12021552903A1 (en) 2022-04-04
CL2023003696A1 (es) 2024-06-14
CL2023003694A1 (es) 2024-06-14
CO2021015254A2 (es) 2021-11-19
CN113966343A (zh) 2022-01-21

Similar Documents

Publication Publication Date Title
MA56205A (fr) Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
EP3826612A4 (fr) Nouveaux anticorps monoclonaux spécifiques à cldn 18.2 et leurs méthodes d'utilisation
EP3852805A4 (fr) Anticorps anti-lilrb2 et leurs méthodes d'utilisation
EP3801551A4 (fr) Compositions comprenant des composés bisfluoroalkyl-1,4-benzodiazépinone et des agents immunothérapeutiques et leurs méthodes d'utilisation
EP3634995A4 (fr) Anticorps se liant spécifiquement à pd-1 et leurs méthodes d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
EP3902834A4 (fr) Compositions hétérodimeres d'anticorps à spécifiques et à tétravalents, et utilisations de celles-ci
EP3959318A4 (fr) Compositions d'oligonucléotides et leurs méthodes d'utilisation
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
EP3826641A4 (fr) Compositions d'anticorps anti-fcrn et leurs procédés d'utilisation
MA49457A (fr) Molécules d'anticorps se liant à cd73 et leurs utilisations
EP3464346A4 (fr) Anticorps, composition et kits les comprenant et leurs procédés d'utilisation
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
MA54955A (fr) Anticorps anti-claudine 6 et leurs utilisations
EP3953385A4 (fr) Anticorps cd19 et leurs procédés d'utilisation
EP4004051A4 (fr) Anticorps immunomodulateurs et leurs méthodes d'utilisation
EP3684369A4 (fr) Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie
MA54148A (fr) Mélanges et compositions comprenant de la 5-fluoro-4-imino-3-méthyl-1-tosyl-3,4-dihydropyrimidin-2-one et leurs procédés d'utilisation
EP4028034A4 (fr) Protéines réceptrices orthogonales chimériques et leurs méthodes d'utilisation
EP3773716A4 (fr) Anticorps monoclonaux qui se lient à ssea4 et leurs utilisations
MA55750A (fr) Formulations d'anticorps stables et à faible viscosité et leurs utilisations
EP3955902A4 (fr) Compositions en aérosol comprenant des mitochondries et leurs méthodes d'utilisation
MA53492A (fr) Anticorps anti-cd33 et leurs méthodes d'utilisation